JNJ 39588146

Drug Profile

JNJ 39588146

Alternative Names: JNJ-39588146

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Johnson & Johnson Pharmaceutical Research & Development
  • Developer Janssen Research & Development
  • Class Heart failure therapies
  • Mechanism of Action Corticotropin-releasing hormone stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Heart failure

Most Recent Events

  • 06 Feb 2017 Renova Therapeutics in-licensed stresscopin investigational new drug file from Janssen Pharmaceuticals
  • 30 Sep 2011 Johnson & Johnson completes a phase II trial in Heart failure in Belgium, Germany, Poland & Romania (NCT01120210)
  • 30 Jun 2010 Phase-II clinical trials in Heart failure in Germany (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top